Kezar Life Sciences Stock Forecast, Price & News

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KZR stock has increased by 44.6% and is now trading at $5.77.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kezar Life Sciences.

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Kezar Life Sciences.

Kezar Life Sciences Inc (NASDAQ:KZR) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04.
View Kezar Life Sciences' earnings history.

4 equities research analysts have issued twelve-month price objectives for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 160.0% from the stock's current price.
View analysts' price targets for Kezar Life Sciences.

Some companies that are related to Kezar Life Sciences include Retrophin (RTRX), Supernus Pharmaceuticals (SUPN), BioXcel Therapeutics (BTAI), Innoviva (INVA), Indivior (INVVY), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Nkarta (NKTX), Intercept Pharmaceuticals (ICPT), ImmunoGen (IMGN), Athenex (ATNX), Repare Therapeutics (RPTX), Akero Therapeutics (AKRO), Esperion Therapeutics (ESPR) and Enanta Pharmaceuticals (ENTA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), Opko Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nwam LLC (0.03%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends for Kezar Life Sciences.

KZR stock was bought by a variety of institutional investors in the last quarter, including Nwam LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment, and Vassiliki Economides.
View insider buying and selling activity for Kezar Life Sciences.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $5.77.

Kezar Life Sciences has a market capitalization of $266.90 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]